CollPlant Biotechnologies (CLGN) Common Equity (2017 - 2025)

CollPlant Biotechnologies' Common Equity history runs 9 years deep, the most recent figure standing at $6.1 million for Q4 2025.

• Quarterly Common Equity fell 54.84% year-over-year to $6.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $6.1 million (down 54.84% YoY) and the FY2025 annual result came in at $6.1 million, down 54.84% from the prior year.
• Common Equity was $6.1 million for Q4 2025 at CollPlant Biotechnologies, down from $9.3 million in the prior quarter.
• Across five years, Common Equity topped out at $50.6 million in Q1 2021 and bottomed at $6.1 million in Q4 2025.
• A 5-year average of $30.2 million and a median of $32.3 million in 2022 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity soared 907.84% — and 2025, when it plunged 54.84%.
• CollPlant Biotechnologies' Common Equity stood at $45.1 million in 2021, then retreated by 28.46% to $32.3 million in 2022, then declined by 12.21% to $28.3 million in 2023, then tumbled by 52.49% to $13.5 million in 2024, then tumbled by 54.84% to $6.1 million in 2025.
• Business Quant data shows CLGN's Common Equity at $6.1 million in Q4 2025, $9.3 million in Q3 2025, and $12.5 million in Q2 2025.